Chloroquine-d₅

Cat. No.: HY-17589AS Purity: 100.00%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Chloroquine-d₅ is deuterium labeled Chloroquine. Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM)[1][2][3][4].

For research use only. We do not sell to patients.

Chloroquine-d<sub>5</sub> Chemical Structure

Chloroquine-d₅ Chemical Structure

CAS No. : 1854126-41-2

Size	Price	Stock	Quantity
1 mg	USD 380	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 970	Get quote	Estimated Time of Arrival: December 31
10 mg		Get quote
50 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Chloroquine-d₅:

1 Publications Citing Use of MCE Chloroquine-d₅

•Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121. [Abstract]

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Parasite Isoform Specific Products:

View All Isoforms

View All Toll-like Receptor (TLR) Isoform Specific Products:

View All Isoforms

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]^[2][3]^[5]

Plasmodium

Malaria

TLRs

SARS-COV-2

HIV-1

Molecular Weight

324.90

Formula

C₁₈H₂₁D₅ClN₃

CAS No.

1854126-41-2

Appearance

Liquid

Color

Colorless to light yellow

SMILES

CC(NC1=CC=NC2=CC(Cl)=CC=C12)CCCN(CC)C([2H])([2H])C([2H])([2H])[2H]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Purity & Documentation

Purity: 100.00%

Select Batch:

Data Sheet (270 KB) SDS (251 KB)

COA (245 KB) LCMS (179 KB)

Handling Instructions (2659 KB)

References

[1]. Said A, et al. Chloroquine promotes IL-17 production by CD4+ T cells via p38-dependent IL-23 release by monocyte-derived Langerhans-like cells. J Immunol. 2014 Dec 15;193(12):6135-43. [Content Brief]

[2]. Tuomela J, et al. Chloroquine has tumor-inhibitory and tumor-promoting effects in triple-negative breast cancer. Oncol Lett. 2013 Dec;6(6):1665-1672. [Content Brief]

[3]. Mohamed FE, et al. Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2014 Jul 2. doi: 10.1111/liv.12626. [Content Brief]

[4]. Colson P, et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55(4):105932. [Content Brief]

[5]. Savarino A, et al. The anti-HIV-1 activity of chloroquine. J Clin Virol. 2001;20(3):131-135. [Content Brief]